CROs as Early-Stage Life Science Investors? ‘It’s the Model of the Future,’ One Says


Contract research organizations make good money providing critical services to young biotech and drug development companies early on. But often, those companies are cash-strapped at the stage when they need a CRO. That’s why some CROs are becoming stakeholders in the companies they work with, offering cash or services for equity in life science startups…

Comments are closed.